The diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer site

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F15%3A%230000606" target="_blank" >RIV/00209805:_____/15:#0000606 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.hh.um.es/Abstracts/Vol_30/30_5/30_5_503.htm" target="_blank" >http://www.hh.um.es/Abstracts/Vol_30/30_5/30_5_503.htm</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.14670/HH-30.503" target="_blank" >10.14670/HH-30.503</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer site

Popis výsledku v původním jazyce

p63 and p73, the two other members of the p53 family, were identified almost 15 years ago. Here, we review their potential use for diagnosis, prognosis and prediction of response to therapy in various cancers. The two genes show distinct expression patterns in both normal and cancer tissues and each gene gives rise to multiple protein isoforms with different activities, including those with tumour-suppressor or oncogenic effects. Despite such complexity, some common themes emerge; p63 is commonly overexpressed as the ?Np63 isoform and sometimes associated with TP63 amplification, whereas p73 is often reduced (by methylation or gene loss), or there is an increase in the ratio of ?Np73 to TAp73. These generalisations do not apply universally; TAp63 is overexpressed in haematological malignancies, TP63 mis-sense mutations have been reported in squamous cancers and TP63 translocations occur in lymphomas and some lung adenocarcinomas. There are associations with disease prognosis and respon

Název v anglickém jazyce

The diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer site

Popis výsledku anglicky

p63 and p73, the two other members of the p53 family, were identified almost 15 years ago. Here, we review their potential use for diagnosis, prognosis and prediction of response to therapy in various cancers. The two genes show distinct expression patterns in both normal and cancer tissues and each gene gives rise to multiple protein isoforms with different activities, including those with tumour-suppressor or oncogenic effects. Despite such complexity, some common themes emerge; p63 is commonly overexpressed as the ?Np63 isoform and sometimes associated with TP63 amplification, whereas p73 is often reduced (by methylation or gene loss), or there is an increase in the ratio of ?Np73 to TAp73. These generalisations do not apply universally; TAp63 is overexpressed in haematological malignancies, TP63 mis-sense mutations have been reported in squamous cancers and TP63 translocations occur in lymphomas and some lung adenocarcinomas. There are associations with disease prognosis and respon

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Histology and histopathology

ISSN

0213-3911

e-ISSN

—

Svazek periodika

30

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

ES - Španělské království

Počet stran výsledku

19

Strana od-do

503-521

Kód UT WoS článku

000352500300001

EID výsledku v databázi Scopus

2-s2.0-84929762237